This review summarizes recent progress in the development of myostatin inhibitors for the treatment of muscle wasting disorders. It also focuses on findings in myostatin biology that may have implications for the development of antimyostatin therapies.
INTRODUCTION
Cachexia is a wasting syndrome exhibited by many cancer patients particularly at advanced stages of disease. It is characterized by the loss of skeletal muscle mass (with or without fat loss), despite adequate nutritional intake. Cancer cachexia is associated with diminished quality of life, functional performance and decreased survival. Cancer-related muscle loss is an independent predictor of poor outcome linked to increased immobility and mortality, and has also been associated with intolerance to chemotherapy. There has been increasing interest in therapeutic interventions that prevent, delay or treat cancer-related muscle wasting, in hopes of improving outcomes for the cancer patient. Some recent reviews and key articles in this area are available [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
There are many commonalities at the molecular level in the pathways in skeletal muscle that result in atrophy, whether it is in the context of cancer cachexia or other noncancer muscle wasting situations. The mechanisms regulating skeletal muscle mass have recently been reviewed [17] [18] [19] [20] [21] . Myostatin has emerged as an intriguing therapeutic target [22] . Myostatin, a member of the TGFb superfamily of growth factors, is a highly conserved negative regulator of skeletal muscle mass that is upregulated in many conditions of muscle wasting. Various induced or natural conditions leading to myostatin deficiency result in increased muscle mass and strength in normal animals and have been shown to treat or prevent a range of muscle wasting conditions.
The myostatin signaling pathway and its role in regulating skeletal muscle has been recently reviewed [23, 24] . At the molecular level, myostatin binds to and activates the activin receptor IIB (ActRIIB)/Alk 4/5 complex (Fig. 1) . Although ActRIIB/Alk4/5 is broadly expressed, myostatin is produced and exhibits its effects primarily on skeletal muscle.
Many approaches are being taken both preclinically and clinically to inhibit the myostatin signaling pathway (Fig. 1) . The majority of these approaches acts extracellularly to block myostatin engaging with the ActRIIB/Alk4/5 receptor complex, either by binding directly to myostatin itself or by binding to components of this receptor complex. Due to the fact that multiple ligands signal through, and therefore bind, ActRIIB apart from myostatin (including activin A, gdf11, bmp9) [25] [26] [27] the approaches that target the ActRIIB receptor or use ActRIIB as a soluble decoy receptor may not specifically block myostatin action.
Similarly, the naturally occurring myostatin binding proteins follistatin and Fstl3 are known to bind a number of growth factors in addition to myostatin [28, 29] . The added risk/benefit of these multitargeted approaches is under investigation (see below).
PROGRESS IN VALIDATION OF MYOSTATIN AS A TARGET FOR MUSCLE WASTING DISORDERS

Preclinical results
Two recent studies, performed in mouse models of cancer cachexia, have examined the effects of myostatin inhibitors on physical performance and muscle function, building on previous data that showed positive effects on muscle mass [30, 31] . Mice with Lewis Lung carcinoma treated with ActRIIB-Fc ( Fig. 1 Myostatin inhibitors work to induce muscle hypertrophy predominantly through effects on myofibrillar protein synthesis rather than stimulating satellite cell proliferation.
Myostatin deficiency is able to increase total force in normal mice but specific force is compromised due, at least in part, to reduced MND size in the myofibers in these hypertrophied muscles. Treating disorders with, where muscle is atrophied and MND size is below normal, with myostatin inhibitors, has not been confounded by such issues. Myostatin has been reported to be expressed by a number of murine and human tumor cell lines.
consistently improve the underlying weakness of dystrophic muscle. There has been hope that myostatin inhibitors might attenuate the muscle fibrosis that is a hallmark of muscular dystrophy, given myostatin's role in inducing dystrophic muscle fibroblast proliferation [ [46] ], showed improvement in fibrosis with myostatin antibody or myostatin propeptide treatment, respectively, no improvement on muscle histopathology was seen after ActRIIB-Fc treatment of mdx mice [40, 42] . It has been suggested that the degree of muscle disease at the time of treatment may influence outcome [43] . Human muscular dystrophy disorders display paradoxical muscle wasting and selective hypertrophy of skeletal muscles, leading to imbalance, contractures and postural instabilities [37 && ]. When the muscle hypertrophic myostatin heterozygote whippet [47] was crossed with the GRMD dog, selective muscle hypertrophy seen in the GRMD dog was exaggerated resulting in more pronounced postural instability and worsened clinical scores, cautioning that further hypertrophy of already selective hypertrophic muscle in muscular dystrophy may not be beneficial [37 && ]. Dysferlin null mice, a model of dysferlin-deficiency muscular dystrophy [48] , expressing the myostatin inhibitor follistatin, demonstrated a transient increase in muscle mass followed by decreased muscle mass and function and increased muscle fibrosis There is excitement regarding disease-modifying therapies currently in clinical development for muscular dystrophy based on exon skipping methods, which overcome the underlying genetic defect of the dystrophin gene and improve specific muscle force without effects on muscle mass [reviewed in [49, 50] the investigation of myostatin inhibitors for the treatment of severe neuromuscular disorders [54 & ,55]. However, SOD1 null mice, a model of amyotrophic lateral sclerosis, did not exhibit any improvements in survival (despite improvements in muscle mass) when exposed to myostatin inhibitors [56] . In another report, crossing of SMN null mice, a model of Spinal Muscular Atrophy, with myostatin null mice did not lead to increases in muscle mass or effects on survival [57] , consistent with results using myostatin inhibitors from Sumner et al. [58] but inconsistent with the positive effects reported by Rose et al. [59] . In contrast to the above reports, treatment of the myotubularin-deficient mouse, a model of X-linked myotubular myopathy, with ActRIIB-Fc did lead to transient increases in muscle mass and strength and a 17% increase in survival [60 && ].
Other animal models of muscle wasting have been used to determine if inhibition of myostatin has therapeutic potential in treating a range of muscle wasting conditions. Positive results have been reported in models of chronic kidney disease, disuse atrophy and age and hypogonadism-induced muscle loss [61,62 & ,63] . Overexpression of the myostatin interacting protein GASP1 [64] has been shown to induce muscular hypertrophy in mice but has not yet been tested in models of muscle wasting. Identification of myostatin-blocking decorin peptides are at an even earlier stage of preclinical development [65] . There is increasing preclinical evidence to suggest that inhibition of myostatin may also have metabolic benefits. Myostatin deficiency or myostatin inhibition in mice has been shown to result in decreased fat mass and increased insulin sensitivity raising the therapeutic potential of myostatin inhibition in obesity and insulin resistance associated with obesity [reviewed in [23] ].
Clinical results
Some myostatin inhibitors have progressed into clinical development as summarized in Table 1. LY2495655 is a myostatin antibody that is currently in clinical development for muscle wasting associated with cancer and other disorders (see Table  1 ). Results of a study in healthy volunteers demonstrated the drug to be well tolerated and led to an increase in thigh muscle volume (TMV) [66 && ]. Interim results of a Phase 1 safety study of LY2495655 in advanced cancer patients without chemotherapy reported that a maximum tolerated dose was not reached and increased muscle volume with concomitant increases in hand grip strength and other functional measures were observed; however, a clear dose-response was not observed, ascribed to small sample size and patient heterogeneity [66 && ]. A Phase 2 trial of LY2495655 in patients with locally advanced/inoperable or metastatic pancreatic cancer receiving standard of care chemotherapy is ongoing with overall survival as the primary endpoint of the trial (Table 1) .
BYM-338 is an antibody directed to ActRIIB that is currently in Phase 2 for the treatment of cachexia in patients with stage IV nonsmall cell lung cancer or Stage III/IV adenocarcinoma of the pancreas. The primary endpoint of the trial is TMV at 8 weeks as measured by MRI. BYM-338 is also in Phase 2 trials for other muscle wasting disorders (Table 1) . Single infusions of BYM-334 in healthy volunteers were reported to be well tolerated and resulted in an increase in TMV (D. Rook; International conference on sarcopenia research, Orlando, December 2012).
The correlation of increases in muscle volume to clinically meaningful functional outcomes for patients treated with myostatin inhibitors still awaits validation. Interestingly, myostatin protein levels were found to be upregulated in muscle biopsies taken from early stage gastric cancer patients even before significant weight loss (>10%) had occurred, leading to the suggestion of early intervention to prevent cancer cachexia [67 & ]. Clinical development of myostatin inhibitors for the treatment of muscular dystrophy has made recent progress [49, 68] . Phase 1/2 results of MYO-029, a myostatin antibody, failed to show effects on muscle strength or function in adult Becker, limbgirdle and facioscapulohumeral muscular dystrophy patients [69] . PF-06252616 is a myostatin antibody currently in Phase 1 testing in healthy volunteers; it was recently given orphan drug designation by the European Medical Agency (EMA) for treatment of Duchenne muscular dystrophy (DMD). ACE-031, a human ActRIIB-Fc, in single and multiple ascending studies in healthy volunteers showed significant increases in lean body mass (LBM) and TMV [ telangiectasias type 2 [72] , and the elucidation of the Alk1/ActRIIB complex as the main signaling pathway for BMP9 [27, 73] warrant further investigation into this particular ligand. Skeletal muscle weakness is associated with a large array of conditions that involve muscle wasting ranging from age-related atrophy, termed sarcopenia, to the wasting associated with immobility, termed disuse atrophy (reviewed in [18, 22] ). Several clinical trials are in progress that seek to prove the concept that myostatin inhibitors may be therapeutically beneficial and provide meaningful benefit to these wasting states. Trials are ongoing in chronic obstructive pulmonary disease (COPD) patients, in rehabilitation postorthopedic surgery/ hip replacement subjects and in the sarcopenic adult and older weak fallers (Table 1 ). In a Phase 2 trial in sporadic inclusion body myositis (sIBM), a rare autoimmune disorder [74] , BYM-338 was able to increase LBM, TMV and improve quadriceps strength and 6MWD (Amato et al. Annual MDA conference, San Diego, 2013; Table 1 ).
EMERGING MYOSTATIN PATHWAY BIOLOGY WITH IMPLICATIONS FOR THERAPEUTIC TARGETING: ROLE OF SATELLITE CELLS IN HYPERTROPHY OF SKELETAL MUSCLE INDUCED BY MYOSTATIN DEFICIENCY
In general muscles enlarged beyond normal size, or 'supersized' as a result of myostatin deficiency have increased total force but reduced specific force [75] [76] [77] [78] . In myostatin null mice, the increase in total force does not match the increase in muscle mass [79] . Analysis of the contractility of single fibers from MSTN null mice demonstrated that the specific force deficits were at the level of the muscle myofiber [80, 81 && ]. Historically, it has been thought that a major function of myostatin was to maintain muscle satellite cell quiescence and that the relief of this inhibitory influence led to satellite proliferation and fusion to existing myofibers resulting in hypertrophy, akin to the mechanisms of muscle enlargement after exercise [81 && ,82] . However, recent evidence demonstrates that myostatin exerts its effects directly on the myofiber with little effect on satellite cell activity [83 & ]. The number of myonuclei in muscle is unchanged between normal and myostatin null mice resulting in larger ratios of cytoplasm volume : nuclei or myonuclear domains (MNDs) in null mice [ & ]. These findings suggest that myostatin inhibition in mice leading to 'supersized' muscles occurs with minimal satellite cell activation and can lead to a MND size in which there may not be concomitant increases in function. It remains to be determined if this same mechanism is active in man but with the increased attention and speculation around misuse of myostatin inhibitors this might prove to be a blessing in disguise [89, 90] . As exemplified above, treating disorders with myostatin inhibitors in which muscle is atrophied and MND size is below normal has not been confounded by negative effects on specific force measures. These results also suggest that myostatin inhibitors would be effective in states of satellite cell dysfunction or depletion such as muscular dystrophy [91] .
Emerging linkage of myostatin with tumor biology
Perhaps not surprisingly skeletal muscle tumors, specifically rhabdomyosarcomas (RMS), the most common soft tissue tumor in children, are known to overexpress myostatin [92] . Blocking myostatin activity with a dominant negative form of ActRIIB resulted in decreased proliferation and promoted differentiation of a human RMS cell line suggesting that myostatin inhibition may be a valuable target for interventions for RMS [93] . More interestingly, Lokireddy et al. [94 && ] for the first time reported that myostatin protein is expressed and secreted from the mouse adenocarcinoma cell line C26, and from several human cancer cell lines. A characterization of myostatin expression in primary tumors is warranted in light of these initial findings.
CONCLUSION
There are a number of intervention points being exploited to inhibit myostatin signaling in order to enhance muscle mass under the conditions of muscle atrophy. Many of these therapies have now progressed into early stage clinical trials. Results of several Phase 2 trials underway are awaited to determine if increased muscle volumes translate into muscle strength, performance and outcomes that are clinically meaningful to patients. 
